Natco Pharma Ltd said consolidated net profit had declined 39.4 per cent at ₹63.40 crore in the third quarter ended December 31, 2020 against ₹104 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company declined 24.7 per cent at ₹386 crore compared to ₹513 crore in the same period last year.
Also read:
“The decline in revenue and profits was due to lower sales in domestic oncology and weak realisation of profits from Oseltamivir in the USA,” the company said in a release issued on Thursday.
The board of directors has recommended a third interim dividend of ₹1 per equity share of face value ₹2 each.